<p>Design Therapeutics（纳斯达克代码：DSGN - 获取免费报告）于周三发布了其财报。该公司报告本季度每股收益为（$0.30），超出分析师一致预期的（$0.34）$0.04，Zacks 报道。</p>
<p>获取 <strong>Design Therapeutics</strong> 的提醒：</p>
<h2>Design Therapeutics 股票表现</h2>
<p>周三中午交易时，Design Therapeutics 股票上涨 $0.31，达到 $6.55。该股票交易了 86,016 股，较其平均交易量 194,359 股有所减少。Design Therapeutics 的 12 个月低点为 $2.60，12 个月高点为 $7.77。该公司的 50 日简单移动平均为 $6.26，200 日简单移动平均为 $4.84。该公司的市值为 $3.7302 亿，市盈率为 -5.85，贝塔值为 1.67。</p>
<h2>华尔街分析师预测增长</h2>
<p>另外，Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Design Therapeutics 股票的 &#34;卖出（d-）&#34;评级。根据 MarketBeat.com 的数据，一位股票研究分析师对该股票给予了卖出评级，目前 Design Therapeutics 的平均评级为 &#34;卖出&#34;。</p>
<p><strong>查看我们关于 Design Therapeutics 的最新报告</strong></p>
<h2>机构资金流入和流出</h2>
<p>几家对冲基金和其他机构投资者最近买入和卖出了 DSGN 股票。Invesco Ltd. 在第二季度将其在 Design Therapeutics 的持股增加了 26.8%。Invesco Ltd. 目前拥有 14,364 股该公司的股票，价值 $48,000，此前在上个季度购买了额外的 3,033 股。Jane Street Group LLC 在第一季度购买了 Design Therapeutics 的新头寸，价值约 $70,000。美国银行公司 DE 在第二季度将其在 Design Therapeutics 的持股增加了 11.1%。美国银行公司 DE 目前拥有 24,625 股该公司的股票，价值 $83,000，此前在上个季度购买了额外的 2,459 股。Strs Ohio 在第一季度购买了 Design Therapeutics 的新股份，价值约 $87,000。最后，Bridgeway Capital Management LLC 在第二季度将其在 Design Therapeutics 的持股增加了 65.4%。Bridgeway Capital Management LLC 目前拥有 188,200 股该公司的股票，价值 $634,000，此前在上个季度购买了额外的 74,400 股。对冲基金和其他机构投资者持有该公司 56.64% 的股票。</p>
<h2>Design Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Design Therapeutics, Inc 是一家生物制药公司，专注于研究、设计、开发和商业化小分子治疗药物，以治疗美国的遗传疾病。该公司利用其 GeneTAC 平台设计和开发因核苷酸重复扩展引起的遗传疾病的治疗候选药物。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Design Therapeutics</li>
<li>投资商品：它们是什么？如何投资？</li>
<li>目前三只现金充裕的高增长潜力股票</li>
<li>你应该将这些沃伦·巴菲特的股票加入你的投资组合吗？</li>
<li>为什么 Vertical Aerospace 股票在这次飞行测试后可能会翻倍</li>
<li>如何从价值投资中获利</li>
<li>亚马逊：突破确认——接下来可能会去哪里</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFNHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFNHTg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Design Therapeutics 吗？</h2>
<p>在你考虑 Design Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前... 而 Design Therapeutics 并不在名单上。</p>
<p>虽然 Design Therapeutics 目前在分析师中获得了减持评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

DSGN

<p>Design Therapeutics（纳斯达克代码：DSGN）报告的季度每股收益为（$0.30），超出预期$0.04。股价上涨至$6.55，市值为 3.7302 亿美元。分析师维持 “卖出” 评级，Weiss Ratings 给予 “卖出（d-）” 评级。机构投资者持有 56.64% 的股份，Invesco 和美国银行的持股显著增加。Design Therapeutics 专注于利用其 GeneTAC 平台开发针对遗传疾病的小分子药物</p>

<p>Design Therapeutics (NASDAQ:DSGN - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.34) by $0.04, Zacks reports.</p>
<div class="lb-trans"><p>Design Therapeutics（纳斯达克代码：DSGN - 获取免费报告）于周三发布了其财报。该公司报告本季度每股收益为（$0.30），超出分析师一致预期的（$0.34）$0.04，Zacks 报道。</p>
</div><p>Get <strong>Design Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Design Therapeutics</strong> 的提醒：</p>
</div><h2>Design Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Design Therapeutics 股票表现</h2>
</div><p>Shares of Design Therapeutics stock traded up $0.31 during mid-day trading on Wednesday, hitting $6.55. 86,016 shares of the stock were exchanged, compared to its average volume of 194,359. Design Therapeutics has a 12 month low of $2.60 and a 12 month high of $7.77. The company has a 50-day simple moving average of $6.26 and a 200 day simple moving average of $4.84. The company has a market capitalization of $373.02 million, a P/E ratio of -5.85 and a beta of 1.67.</p>
<div class="lb-trans"><p>周三中午交易时，Design Therapeutics 股票上涨 $0.31，达到 $6.55。该股票交易了 86,016 股，较其平均交易量 194,359 股有所减少。Design Therapeutics 的 12 个月低点为 $2.60，12 个月高点为 $7.77。该公司的 50 日简单移动平均为 $6.26，200 日简单移动平均为 $4.84。该公司的市值为 $3.7302 亿，市盈率为 -5.85，贝塔值为 1.67。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Separately, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Design Therapeutics in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Design Therapeutics currently has an average rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Design Therapeutics 股票的 &#34;卖出（d-）&#34;评级。根据 MarketBeat.com 的数据，一位股票研究分析师对该股票给予了卖出评级，目前 Design Therapeutics 的平均评级为 &#34;卖出&#34;。</p>
</div><p><strong>View Our Latest Report on Design Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Design Therapeutics 的最新报告</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of DSGN. Invesco Ltd. increased its position in shares of Design Therapeutics by 26.8% during the 2nd quarter. Invesco Ltd. now owns 14,364 shares of the company's stock valued at $48,000 after purchasing an additional 3,033 shares during the last quarter. Jane Street Group LLC purchased a new position in Design Therapeutics in the first quarter valued at about $70,000. Bank of America Corp DE increased its stake in shares of Design Therapeutics by 11.1% during the 2nd quarter. Bank of America Corp DE now owns 24,625 shares of the company's stock worth $83,000 after purchasing an additional 2,459 shares during the last quarter. Strs Ohio bought a new stake in shares of Design Therapeutics in the 1st quarter worth approximately $87,000. Finally, Bridgeway Capital Management LLC lifted its stake in Design Therapeutics by 65.4% in the second quarter. Bridgeway Capital Management LLC now owns 188,200 shares of the company's stock valued at $634,000 after purchasing an additional 74,400 shares during the last quarter. Hedge funds and other institutional investors own 56.64% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近买入和卖出了 DSGN 股票。Invesco Ltd. 在第二季度将其在 Design Therapeutics 的持股增加了 26.8%。Invesco Ltd. 目前拥有 14,364 股该公司的股票，价值 $48,000，此前在上个季度购买了额外的 3,033 股。Jane Street Group LLC 在第一季度购买了 Design Therapeutics 的新头寸，价值约 $70,000。美国银行公司 DE 在第二季度将其在 Design Therapeutics 的持股增加了 11.1%。美国银行公司 DE 目前拥有 24,625 股该公司的股票，价值 $83,000，此前在上个季度购买了额外的 2,459 股。Strs Ohio 在第一季度购买了 Design Therapeutics 的新股份，价值约 $87,000。最后，Bridgeway Capital Management LLC 在第二季度将其在 Design Therapeutics 的持股增加了 65.4%。Bridgeway Capital Management LLC 目前拥有 188,200 股该公司的股票，价值 $634,000，此前在上个季度购买了额外的 74,400 股。对冲基金和其他机构投资者持有该公司 56.64% 的股票。</p>
</div><h2>Design Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Design Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.</p>
<div class="lb-trans"><p>Design Therapeutics, Inc 是一家生物制药公司，专注于研究、设计、开发和商业化小分子治疗药物，以治疗美国的遗传疾病。该公司利用其 GeneTAC 平台设计和开发因核苷酸重复扩展引起的遗传疾病的治疗候选药物。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Design Therapeutics</li>
<li>Investing in Commodities: What Are They? How to Invest in Them</li>
<li>3 Cash-Rich Stocks With High Growth Potential Right Now</li>
<li>Should You Add These Warren Buffett Stocks to Your Portfolio?</li>
<li>Why Vertical Aerospace Stock Could Double After This Flight Test</li>
<li>How to Profit From Value Investing</li>
<li>Amazon: Breakout Confirmed—Here’s Where It Could Go Next</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Design Therapeutics</li>
<li>投资商品：它们是什么？如何投资？</li>
<li>目前三只现金充裕的高增长潜力股票</li>
<li>你应该将这些沃伦·巴菲特的股票加入你的投资组合吗？</li>
<li>为什么 Vertical Aerospace 股票在这次飞行测试后可能会翻倍</li>
<li>如何从价值投资中获利</li>
<li>亚马逊：突破确认——接下来可能会去哪里</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFNHTg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=DSGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Design Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Design Therapeutics 吗？</h2>
</div><p>Before you consider Design Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Design Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Design Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前... 而 Design Therapeutics 并不在名单上。</p>
</div><p>While Design Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Design Therapeutics 目前在分析师中获得了减持评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Design Therapeutics（纳斯达克代码：DSGN）公布季度财报，每股收益比预期高出 0.04 美元